When Professor Michael Good first arrived at Griffith University seven years ago he never imagined that a vaccine to protect against the nasty Streptococcus A infection would already be at pharmaceutical development stage. But with the support of Vice Chancellor Ian O’Connor, Institute for Glycomics Director Professor Mark von Itzstein and a remarkable research team […]
Griffith University will partner with a Chinese pharmaceutical for a new vaccine that has enormous potential to help millions. Clinical trials of the new, needle-free vaccine is targeted at Streptococcus A infection, the cause of strep throat and rheumatic heart disease and many other illnesses.
Development of a vaccine that can treat the bacteria which causes Scarlet Fever and can lead to rheumatic fever, has the potential to save the lives of many Indigenous Australians and other lives worldwide.
Griffith launches human trials for a vaccine against Streptococcus A, the germ that causes rheumatic fever.